Dr. Bodo Lange is a seasoned cell biologist.

He was a postdoctoral researcher at the University of Manchester (UK), KARC (Kobe, Japan), and EMBL (Heidelberg). Subsequently, he served as group leader at the Max Planck Institute for Molecular Genetics (Berlin) and as lecturer at Freie Universität Berlin.

Dr. Lange led MUTANOM, a BMBF-funded consortium project, investigating the effects of driver gene mutations on protein-protein interactions and signaling networks. He co-authored over 30 research articles.  He was member of the executive committee fort he IMI OncoTrack  project and coordinated the Horizon 2020 CanPathPro two pre-clinical projects in the field of predictive modeling of cancer signaling pathways. He became CEO of Alacris in 2011.